1 month 60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates Zacks
60 Degrees Pharmaceuticals Inc. (SXTP) delivered earnings and revenue surprises of -55% and 60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
X